Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Ghannoum

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
Advances in Dental Research|March 29, 2011
Overview of the oral HIV/AIDS Research Alliance ProgramC H Shiboski, J Y Webster-Cyriaque, M Ghannoum, et al.
Diagnostic Microbiology and Infectious Disease|January 13, 1999
Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patientsM Pfaller, J Zhang, S Messer, et al.
Oral Diseases|April 26, 2016
The Oral HIV/AIDS Research Alliance Program: lessons learned and future directionsC H Shiboski, J Y Webster-Cyriaque, M Ghannoum, et al.
Journal of Chemotherapy (Florence, Italy)|April 18, 2000
A head-on comparison of the in vitro antifungal activity of conventional and lipid-based amphotericin B: a multicenter studyC Jessup, G Reyes, A Fothergill, et al.
Journal of Clinical Microbiology|May 1, 1996
Multicenter evaluation of broth microdilution method for susceptibility testing of Cryptococcus neoformans against fluconazoleH Sanati, S A Messer, M Pfaller, et al.
Advances in Dental Research|March 29, 2011
New approaches to Candida and oral mycotic infections: Workshop 2AM McCullough, L L Patton, M Coogan, et al.
Antimicrobial Agents and Chemotherapy|October 2, 2019
Activity of a novel 1,3-beta-D-glucan Synthase Inhibitor, Ibrexafungerp (formerly SCY-078), Against <i>Candida glabrata</i>M Ghannoum, L Long, N Isham, et al.
Antimicrobial Agents and Chemotherapy|March 20, 2019
A Novel 1,3-Beta-d-Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of VulvovaginitisE L Larkin, L Long, N Isham, et al.
Antimicrobial Agents and Chemotherapy|April 4, 2018
Evaluation of the Antifungal Activity of the Novel Oral Glucan Synthase Inhibitor SCY-078, Singly and in Combination, for the Treatment of Invasive AspergillosisM Ghannoum, L Long, E L Larkin, et al.
Medical Mycology|February 24, 2001
New targets and delivery systems for antifungal therapyT J Walsh, M A Viviani, E Arathoon, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Advances in Dental Research|March 29, 2011
Overview of the oral HIV/AIDS Research Alliance ProgramC H Shiboski, J Y Webster-Cyriaque, M Ghannoum, et al.
Diagnostic Microbiology and Infectious Disease|January 13, 1999
Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patientsM Pfaller, J Zhang, S Messer, et al.
Oral Diseases|April 26, 2016
The Oral HIV/AIDS Research Alliance Program: lessons learned and future directionsC H Shiboski, J Y Webster-Cyriaque, M Ghannoum, et al.
Journal of Chemotherapy (Florence, Italy)|April 18, 2000
A head-on comparison of the in vitro antifungal activity of conventional and lipid-based amphotericin B: a multicenter studyC Jessup, G Reyes, A Fothergill, et al.
Journal of Clinical Microbiology|May 1, 1996
Multicenter evaluation of broth microdilution method for susceptibility testing of Cryptococcus neoformans against fluconazoleH Sanati, S A Messer, M Pfaller, et al.
Advances in Dental Research|March 29, 2011
New approaches to Candida and oral mycotic infections: Workshop 2AM McCullough, L L Patton, M Coogan, et al.
Antimicrobial Agents and Chemotherapy|October 2, 2019
Activity of a novel 1,3-beta-D-glucan Synthase Inhibitor, Ibrexafungerp (formerly SCY-078), Against <i>Candida glabrata</i>M Ghannoum, L Long, N Isham, et al.
Antimicrobial Agents and Chemotherapy|March 20, 2019
A Novel 1,3-Beta-d-Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of VulvovaginitisE L Larkin, L Long, N Isham, et al.
Antimicrobial Agents and Chemotherapy|April 4, 2018
Evaluation of the Antifungal Activity of the Novel Oral Glucan Synthase Inhibitor SCY-078, Singly and in Combination, for the Treatment of Invasive AspergillosisM Ghannoum, L Long, E L Larkin, et al.
Medical Mycology|February 24, 2001
New targets and delivery systems for antifungal therapyT J Walsh, M A Viviani, E Arathoon, et al.
Pageof 5